Barclays’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Barclays’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-36,510	Closed	-$3.92M	–	5280
2023 Q1	$3.92M	Sell	36,510 -10,222	-22%	-$1.18M	﹤0.01%	1718
2022 Q4	$5.14M	Sell	46,732 -13,199	-22%	-$856K	﹤0.01%	1605
2022 Q3	$3.54M	Buy	59,931 +58,463	+3,982%	+$2.68M	﹤0.01%	1378
2022 Q2	$41K	Sell	1,468 -3,524	-71%	-$102K	﹤0.01%	4115
2022 Q1	$189K	Buy	+4,992	New	+$197K	﹤0.01%	3455

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Barclays's RXDX Position: Q2 2023 in Review

Barclays sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 36,510 shares — an estimated $3.92M sold.

Barclays first reported a position in RXDX in Q1 2022 and held it in 5 quarters. The position peaked at $5.14M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Barclays reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Barclays sold 36,510 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $3.92M.
Barclays first reported a position in Prometheus Biosciences, Inc. Common Stock in Q1 2022 and held it in 5 quarters.
Barclays's Prometheus Biosciences, Inc. Common Stock position peaked at $5.14M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.